2023
Greenhalgh, J., Mahon, J., Houten, R., Edwards, K., Donegan, S., Boland, A., . . . Mcentee, J. (2023). Upadacitinib for treating moderately to severely active ulcerative colitis [ID3953]: Upadacitinib for treating moderately to severely active ulcerative colitis[ID3953]. Retrieved from https://www.fundingawards.nihr.ac.uk/award/NIHR135585
Bromley, R., Adab, N., Bluett-Duncan, M., Clayton-Smith, J., Christensen, J., Edwards, K., . . . Marson, A. G. (2023). Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.. The Cochrane database of systematic reviews, 8, CD010224. doi:10.1002/14651858.cd010224.pub3DOI: 10.1002/14651858.cd010224.pub3
Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child (Conference Paper)
Khanom, S., Adab, N., Bluett-Duncan, M., Clayton-Smith, J., Christensen, J., Edwards, K., . . . Bromley, R. (2023). Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child. In NEUROTOXICOLOGY AND TERATOLOGY Vol. 98. doi:10.1016/j.ntt.2023.107243DOI: 10.1016/j.ntt.2023.107243
Bresnahan, R., Houten, R., Greenhalgh, J., Nevitt, S., Mahon, J., Beale, S., . . . Chaplin, M. (2023). Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. PharmacoEconomics - open. doi:10.1007/s41669-023-00408-zDOI: 10.1007/s41669-023-00408-z
Greenhalgh, J., Mahon, J., Bryning, S., Chaplin, M., Beale, S., Boland, A., . . . Basu, B. (2023). Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]. Retrieved from https://www.nice.org.uk/guidance/gid-ta10920/documents/committee-papers
2021
Bresnahan, R., Houten, R., Mahon, J., Beale, S., Nevitt, S., Greenhalgh, J., . . . Gandhi, S. (2021). Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/rebecca-bresnahan/
Greenhalgh, J., Mahon, J., Nevitt, S., Bresnahan, R., Boland, A., Beale, S., . . . Boon, C. (2021). Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]: Nivolumab in combination with chemotherapy for untreated advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma [ID1465]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Greenhalgh, J., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Chaplin, M., & Green, J. A. (2021). First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (3). doi:10.1002/14651858.CD010383.pub3DOI: 10.1002/14651858.CD010383.pub3
Houten, R., Greenhalgh, J., Mahon, J., Nevitt, S., Beale, S., Boland, A., . . . McEntee, J. (2021). Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 5(1), 13-22. doi:10.1007/s41669-020-00206-xDOI: 10.1007/s41669-020-00206-x
2020
Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743] (Report)
Bresnahan, R., Mahon, J., Nevitt, S., Beale, S., Boland, A., Greenhalgh, J., . . . Campbell, L. (2020). Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]: Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/rebecca-bresnahan/
Sapropterin dihydrochloride for treating phenylketonuria [ID1475] (Report)
Greenhalgh, J., James, M., Nevitt, S., Bresnahan, R., Beale, S., Boland, A., . . . Schwan, B. (2020). Sapropterin dihydrochloride for treating phenylketonuria [ID1475]: Sapropterin dihydrochloride for treating phenylketonuria [ID1475]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468] (Report)
Greenhalgh, J., Lambe, T., Mahon, J., Nevitt, S., Edwards, K., Bresnahan, R., . . . Green, J. (2020). Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]: Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Greenhalgh, J., Lambe, T., Nevitt, S., Mahon, J., Boland, A., Beale, S., . . . Moonim, M. (2020). Midostaurin for treating advanced systemic mastocytosis [ID1573]: Midostaurin for treating advanced systemic mastocytosis [ID1573]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Greenhalgh, J., Weston, J., Dundar, Y., Nevitt, S. J., & Marson, A. G. (2020). Antiepileptic drugs as prophylaxis for postcraniotomy seizures. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (4). doi:10.1002/14651858.CD007286.pub5DOI: 10.1002/14651858.CD007286.pub5
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532] (Report)
Greenhalgh, J., Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., . . . Goodson, N. (2020). Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]: Ixekizumab for treating axial spondyloarthritis after NSAIDs[ID1532]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Duarte, R., Stainthorpe, A., Greenhalgh, J., Richardson, M., Nevitt, S., Mahon, J., . . . Takwoingi, Y. (2020). Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24(3), 1-+. doi:10.3310/hta24030DOI: 10.3310/hta24030
Fleeman, N., Houten, R., Bagust, A., Richardson, M., Beale, S., Boland, A., . . . Shenoy, A. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24(2), 1-+. doi:10.3310/hta24020DOI: 10.3310/hta24020
2019
Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., Dundar, Y., . . . Shenoy, A. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC CANCER, 19(1). doi:10.1186/s12885-019-6369-7DOI: 10.1186/s12885-019-6369-7
Duarte, R., Stainthorpe, A., Mahon, J., Greenhalgh, J., Richardson, M., Nevitt, S., . . . Takwoingi, Y. (2019). Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: A systematic review and economic evaluation. PLOS ONE, 14(12). doi:10.1371/journal.pone.0226671DOI: 10.1371/journal.pone.0226671
Al Hourani, A. (2019, November 1). The Effect of Orthodontic Treatment on Traumatised Teeth: A Systematic Review and Vignette Study.
Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck (Report)
Greenhalgh, J., Mahon, J., Chaplin, M., Nevitt, S., Boland, A., Beale, S., . . . Shaw, R. (2019). Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck: Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck (17/56/06). NICE website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10181/documents/committee-papers
Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer (Report)
Greenhalgh, J., Mahon, J., Chaplin, M., Beale, S., Boland, A., Lambe, T., . . . Palmieri, C. (2019). Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer: Atezolizumab for untreated, locally advanced or metastatic, triple negative breast cancer (128748). NICE website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10433/documents/committee-papers
2018
Encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma (Report)
Greenhalgh, J., Mahon, J., Nevitt, S., Beale, S., Boland, A., Lambe, T., . . . Danson, S. (2018). Encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma: Encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma (17/109/14). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta562/documents/committee-papers
Stainthorpe, A., Greenhalgh, J., Bagust, A., Richardson, M., Boland, A., Beale, S., . . . Palmer, D. (2018). Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(10), 1153-1163. doi:10.1007/s40273-018-0646-1DOI: 10.1007/s40273-018-0646-1
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (Report)
Greenhalgh, J., Mahon, J., Nevitt, S., Beale, S., Boland, A., Lambe, T., . . . Marshall, E. (2018). Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (17/109/17). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta553/documents/committee-papers
Hounsome, J., Greenhalgh, J., Schofield-Robinson, O. J., Lewis, S. R., Cook, T. M., & Smith, A. F. (2018). Nitrous oxide-based vs. nitrous oxide-free general anaesthesia and accidental awareness in surgical patients: an abridged Cochrane systematic review. ANAESTHESIA, 73(3), 365-374. doi:10.1111/anae.14065DOI: 10.1111/anae.14065
2017
Fleeman, N., Bagust, A., Duarte, R., Chaplin, M., Nevitt, S., Boland, A., . . . Thorp, N. (n.d.). Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen (ID1072). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta515/documents/committee-papers
Hounsome, J., Lee, A., Greenhalgh, J., Lewis, S. R., Schofield-Robinson, O. J., Coldwell, C. H., & Smith, A. F. (2017). A systematic review of information format and timing before scheduled adult surgery for peri-operative anxiety. ANAESTHESIA, 72(10), 1265-1272. doi:10.1111/anae.14018DOI: 10.1111/anae.14018
Feinberg, J., Nielsen, E. E., Greenhalgh, J., Hounsome, J., Sethi, N. J., Safi, S., . . . Jakobsen, J. C. (2017). Drug-eluting stents versus bare-metal stents for acute coronary syndrome. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (8). doi:10.1002/14651858.CD012481.pub2DOI: 10.1002/14651858.CD012481.pub2
Duarte, R., Mahon, J., Nevitt, S., Greenhalgh, J., Boland, A., Beale, S., . . . Mcentee, J. (n.d.). Cladribine for the treatment of relapsing-remitting multiple sclerosis (ID64). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta493/documents/committee-papers
Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer (Report)
Greenhalgh, J. (n.d.). Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer (ID1059). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta535/documents/committee-papers
Greenhalgh, J. (n.d.). Nab-paclitaxel with gemcitabine for 1st line metastatic pancreatic adenocarcinoma (ID1058). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta476/documents/committee-papers
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (Report)
Greenhalgh, J., Bagust, A., Stainthorpe, A., Chaplin, M., Boland, A., De Sousa Rego Vieira Duarte, R., . . . Palmer, D. (2017). Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (14/90/01). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta476/documents/committee-papers
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy (Report)
Greenhalgh, J. (n.d.). Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy (ID970). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta520/documents/committee-papers
Beale, S., Mahon, J., Nevitt, S., Boland, A., Greenhalgh, J., Richardson, M., . . . Green, J. (2017). Atezolizumab for the treatment of people with locally advanced or metastatic non-small lung cancer whose disease has progressed after chemotherapy (ID970).
Greenhalgh, J., Stainthorpe, S., Richardson, M., Duarte, R., Boland, A., Kotas, E., . . . Green, J. (2017). Crizotinib for treating ROS1positive advanced non-small cell lung cancer (D1098).
VP177 Older People With Cancer: To Treat Or Not To Treat With Chemotherapy? (Journal article)
Boland, A., Pilkington, G., Greenhalgh, J., & Dickson, R. (2017). VP177 Older People With Cancer: To Treat Or Not To Treat With Chemotherapy?. International Journal of Technology Assessment in Health Care, 33(S1), 232-233. doi:10.1017/s0266462317004123DOI: 10.1017/s0266462317004123
2016
Feinberg, J., Nielsen, E. E., Greenhalgh, J., Hounsome, J., Sethi, N. J., Safi, S., . . . Jakobsen, J. C. (n.d.). Drug-eluting stents versus bare-metal stents for acute coronary syndrome. doi:10.1002/14651858.cd012481DOI: 10.1002/14651858.cd012481
Nielsen, E. E., Feinberg, J., Greenhalgh, J., Hounsome, J., Sethi, N. J., Safi, S., . . . Jakobsen, J. C. (n.d.). Drug-eluting stents versus bare-metal stents for stable ischaemic heart disease. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd012480DOI: 10.1002/14651858.cd012480
Greenhalgh, J. (n.d.). Palbociclib for treating metastatic, hormone receptor-positive, HER2-negative breast cancer (ID915). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta495/documents/committee-papers-2
Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. (Journal article)
Weston, J., Bromley, R., Jackson, C. F., Adab, N., Clayton-Smith, J., Greenhalgh, J., . . . Marson, A. G. (2016). Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.. The Cochrane database of systematic reviews, 11. doi:10.1002/14651858.CD010224.pub2DOI: 10.1002/14651858.CD010224.pub2
Greenhalgh, J. (n.d.). Ex vivo expanded autologous human corneal epithelial cells for treating moderate to severe limbal stem cell deficiency due to ocular burns (ID899). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta467/documents/committee-papers-3
Greenhalgh, J. (n.d.). Cetuximab for the treatment of squamous cell carcinoma in the head and neck (TA172). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta473/documents/committee-papers
Greenhalgh, J. (n.d.). Eribulin for locally advanced or metastatic breast cancer (ID964). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10030/documents/committee-papers
Hounsome, J., Nicholson, A., Greenhalgh, J., Cook, T. M., Smith, A. F., & Lewis, S. R. (2016). Nitrous oxide-based versus nitrous oxide-free general anaesthesia and accidental awareness during general anaesthesia in surgical patients. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (8). doi:10.1002/14651858.CD011052.pub2DOI: 10.1002/14651858.CD011052.pub2
Greenhalgh, J. (n.d.). Nanoliposomal irinotecan for treating pancreatic cancer after prior treatment with gemcitabine (ID778). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta440/documents/committee-papers-2
Dundar, Y., Greenhalgh, J., Richardson, M., & Dwan, K. (2016). Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta-analysis. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 31(4), 268-285. doi:10.1002/hup.2535DOI: 10.1002/hup.2535
Greenhalgh, J. (n.d.). Everolimus in combination with an aromatase inhibitor for the treatment of advanced or metastatic HER2 negative, oestrogen receptor positive breast cancer after prior endocrine therapy (ID1011). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta421/documents/committee-papers
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer (Journal article)
Greenhalgh, J., Dwan, K., Boland, A., Bates, V., Vecchio, F., Dundar, Y., . . . Green, J. A. (2016). First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD010383.pub2DOI: 10.1002/14651858.CD010383.pub2
Greenhalgh, J. (n.d.). Pemetrexed maintenance treatment following induction therapy with pemetrexed & cisplatin for non-squamous NSLC (TA309). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta402/documents/committee-papers
Greenhalgh, J. (2016). Nivolumab for previously treated locally advanced or metastatic non-small-cell lung cancer (ID811). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta484/documents/committee-papers
Greenhalgh, J. (n.d.). Nivolumab for treating metastatic, non-squamous, non-small-cell lung cancer after chemotherapy (ID900). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta484/documents/committee-papers
Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma (Report)
Greenhalgh, J., Mahon, J., Beale, S., Boland, A., Krishan, A., Chaplin, M., . . . Steven, N. (2016). Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma: Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma (12/50/01). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta396/history
Fleeman, N., Bagust, A., Boland, A., Beale, S., Chaplin, M., Krishan, A., . . . Payne, M. (2016). Talimogene laherparepvec for treating metastatic melanoma: Talimogene laherparepvec for treating metastatic melanoma (14/206/04). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-tag509/documents/committee-papers-2
Greenhalgh, J., Aslam, R. W., Mahon, J., Krishan, A., Boland, A., Beale, S., . . . Green, J. (2016). Osimertinib for treating locally advanced or metastatic EGFR and T790M mutation-positive non-small cell lung cancer: Osimertinib for treating locally advanced or metastatic EGFR and T790M mutation-positive non-small cell lung cancer (ID 874).
Greenhalgh, J., Mahon, J., Boland, A., Beale, S., Krishan, A., Abdulla, A., . . . Green, J. (2016). Pembrolizumab for untreated PD-L1 positive metastatic non-small cell lung cancer: Pembrolizumab for untreated PD-L1 positive metastatic non-small cell lung cancer (ID990).
2015
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Withdrawn Paper. Art. no. CD004587) (Journal article)
Hockenhull, J., Greenhalgh, J., Dickson, R. C., Ricciardi, M., & Patel, A. (2015). Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Withdrawn Paper. Art. no. CD004587). COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (10). Retrieved from https://www.webofscience.com/
Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab (Report)
Fleeman, N., Bagust, A., Chaplin, M., Krishan, A., Boland, A., Beale, S., . . . Payne, M. (2015). Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab: Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab (14/177/07). NICE Website. Retrieved from https://www.nice.org.uk/
Pembrolizumab for treating advanced melanoma in people previously untreated with ipilimumab (Report)
Greenhalgh, J., Mahon, J., Chaplin, M., Krishan, A., Aslam, R., Beale, S., . . . Payne, M. (2015). Pembrolizumab for treating advanced melanoma in people previously untreated with ipilimumab: Pembrolizumab for treating advanced melanoma in people previously untreated with ipilimumab (14/177/06). NICE website. Retrieved from https://www.nice.org.uk/guidance/TA366/documents/committee-papers
2014
First-Line Treatment of Advanced Epidermal Growth Factor Receptor (Egfr) Mutation Positive (M+) Non-Squamous Non-Small Cell (Nsclc) Lung Cancer – a Cochrane Collaboration Meta-Analysis (Journal article)
Green, J. A., Dwan, K., Bates, V., Boland, A., Jain, P., & Greenhalgh, J. (2014). First-Line Treatment of Advanced Epidermal Growth Factor Receptor (Egfr) Mutation Positive (M+) Non-Squamous Non-Small Cell (Nsclc) Lung Cancer – a Cochrane Collaboration Meta-Analysis. Annals of Oncology, 25, iv449. doi:10.1093/annonc/mdu349.55DOI: 10.1093/annonc/mdu349.55
The role of reading on the health and well-being of people with neurological conditions: a systematic review (Journal article)
Latchem, J. M., & Greenhalgh, J. (2014). The role of reading on the health and well-being of people with neurological conditions: a systematic review. AGING & MENTAL HEALTH, 18(6), 731-744. doi:10.1080/13607863.2013.875125DOI: 10.1080/13607863.2013.875125
META-ANALYSIS OF NEURODEVELOPMENTAL OUTCOME FOLLOWING PRENATAL EXPOSURE TO ANTIEPILEPTIC DRUGS (Conference Paper)
Bromley, R. L., Pulman, J. L., Adab, N., Sanniti, A., Greenhalgh, J., McKay, A., . . . Marson, A. G. (2014). META-ANALYSIS OF NEURODEVELOPMENTAL OUTCOME FOLLOWING PRENATAL EXPOSURE TO ANTIEPILEPTIC DRUGS. In EPILEPSIA Vol. 55 (pp. 31). Retrieved from https://www.webofscience.com/
2013
1181 – Short-term management of agitation associated with psychotic or bipolar disorders: a systematic review (Journal article)
Dundar, Y., & Greenhalgh, J. (2013). 1181 – Short-term management of agitation associated with psychotic or bipolar disorders: a systematic review. European Psychiatry, 28, 1. doi:10.1016/s0924-9338(13)76266-7DOI: 10.1016/s0924-9338(13)76266-7
Short term managment of agitation associated with psychotic or bipolar disorders: a systematic review (Conference Paper)
Dundar, Y., Dwan, K., & Greenhalgh, J. (2013). Short term managment of agitation associated with psychotic or bipolar disorders: a systematic review. In European Congress of Psychiatry (pp. 1). Nice: EPA.
2012
The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation (Journal article)
Cherry, M. G., Greenhalgh, J., Osipenko, L., Venkatachalam, M., Boland, A., Dundar, Y., . . . Rees, D. C. (2012). The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 16(43), 1-+. Retrieved from https://www.webofscience.com/
Treatment for epilepsy in pregnancy: congenital malformation outcomes in the child (Chapter)
Pulman, J., Bromley, R., Adab, N., Greenhalgh, J., McKay, A. J., Tudur Smith, C., . . . Marson, A. G. (n.d.). Treatment for epilepsy in pregnancy: congenital malformation outcomes in the child. In J. Pulman (Ed.). John Wiley & Sons, Ltd. doi:10.1002/14651858.cd010224DOI: 10.1002/14651858.cd010224
Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child (Journal article)
Bromley, R., Pulman, J., Adab, N., Greenhalgh, J., Dickson, R. C., McKay, A. J., . . . Marson, A. G. (n.d.). Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. doi:10.1002/14651858.cd010236DOI: 10.1002/14651858.cd010236
2011
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Oyee, J., Blundell, M., . . . Fisher, M. (2011). Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 15(31), 1-+. doi:10.3310/hta15310DOI: 10.3310/hta15310
Increasing pre-school children's consumption of fruit and vegetables. A modelling and rewards intervention. (Journal article)
Horne, P. J., Greenhalgh, J., Erjavec, M., Lowe, C. F., Viktor, S., & Whitaker, C. J. (2011). Increasing pre-school children's consumption of fruit and vegetables. A modelling and rewards intervention.. Appetite, 56(2), 375-385. doi:10.1016/j.appet.2010.11.146DOI: 10.1016/j.appet.2010.11.146
'Increasing pre-school children's consumption of fruit and vegetables. A modelling and rewards intervention.' (Journal article)
Horne, P. J., Greenhalgh, J., Erjavec, M., Lowe, C. F., Viktor, S., & Whitaker, C. J. (2011). 'Increasing pre-school children's consumption of fruit and vegetables. A modelling and rewards intervention.'. Appetite, 56(2), 375-385. doi:10.1016/j.appet.2010DOI: 10.1016/j.appet.2010
2010
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Greenhalgh, J., McLeod, C., Bagust, A., Boland, A., Fleeman, N., Dundar, Y., . . . Pearson, M. (n.d.). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(Suppl 2), 33-39. doi:10.3310/hta14suppl2-05DOI: 10.3310/hta14suppl2-05
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Boland, A., Dundar, Y., . . . Pearson, M. (n.d.). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(Suppl 1), 47-53. doi:10.3310/hta14suppl1-07DOI: 10.3310/hta14suppl1-07
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (n.d.). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health Technology Assessment, 14(Suppl 1), 31-38. doi:10.3310/hta14suppl1-05DOI: 10.3310/hta14suppl1-05
Biofeedback for hypertension: a systematic review. (Journal article)
Greenhalgh, J., Dickson, R., & Dundar, Y. (2010). Biofeedback for hypertension: a systematic review.. Journal of hypertension, 28(4), 644-652. doi:10.1097/hjh.0b013e3283370e20DOI: 10.1097/hjh.0b013e3283370e20
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (2010). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. HEALTH TECHNOLOGY ASSESSMENT, 14, 31-38. doi:10.3310/hta14suppl1/05DOI: 10.3310/hta14suppl1/05
2009
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Fleeman, N., McLeod, C., Dundar, Y., . . . Shaw, R. (n.d.). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technology Assessment, 13(Suppl 3), 49-54. doi:10.3310/hta13suppl3-08DOI: 10.3310/hta13suppl3-08
The effects of biofeedback for the treatment of essential hypertension: a systematic review. (Journal article)
Greenhalgh, J., Dickson, R., & Dundar, Y. (2009). The effects of biofeedback for the treatment of essential hypertension: a systematic review.. Health technology assessment (Winchester, England), 13(46), 1-104. doi:10.3310/hta13460DOI: 10.3310/hta13460
Rituximab for the treatment of rheumatoid arthritis (Journal article)
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., . . . Dickson, R. (n.d.). Rituximab for the treatment of rheumatoid arthritis. Health Technology Assessment, 13(Suppl 2), 23-29. doi:10.3310/hta13suppl2-04DOI: 10.3310/hta13suppl2-04
Greenhalgh, J., Dowey, A. J., Horne, P. J., Fergus Lowe, C., Griffiths, J. H., & Whitaker, C. J. (2009). Positive- and negative peer modelling effects on young children's consumption of novel blue foods.. Appetite, 52(3), 646-653. doi:10.1016/j.appet.2009.02.016DOI: 10.1016/j.appet.2009.02.016
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation (Journal article)
McLeod, C., Fleeman, N., Kirkham, J., Bagust, A., Boland, A., Chu, P., . . . Walley, T. (2009). Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 13(1), 1-+. doi:10.3310/hta13010DOI: 10.3310/hta13010